Clinical trials: Furmonertinib
Non-Small Cell Lung Cancer
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
EGFR-TKI has firmly established itself as a first-line treatment for advanced lung cancer with EGFR-sensitive mutations, and the ADAURA study has added to its indications for use as postoperative adjuvant therapy in early- and…
- Trial name
- NCT05987826
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
NSCLC Patients With Brain Metastasis
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
This study is a Phase III, international, multicenter, randomized, controlled, open-label clinical trial. The primary objective is to evaluate the efficacy and safety of furmonertinib plus platinum-based doublet chemotherapy (Arm…
- Trial name
- NCT06970639
- Testing
- Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Furmonertinib, EGFR-mutation
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in…
- Conditions
- Furmonertinib, EGFR-mutation, NSCLC, Brain Metastases
- Trial name
- NCT05465343
- Testing
- Furmonertinib 160 mg, Q.D.
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking Union Medical College
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
This is a single-armed study designed to evaluate the safety and efficacy of adjuvant targeted-therapy in patients with epidermal growth factor receptor mutation positive stage IB-IIA non-small cell lung carcinoma and high-risk…
- Trial name
- ATHEM (NCT05165355)
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tongji University
Non-Small Cell Lung Cancer
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line treatment with Osmertinib, who were…
- Trial name
- NCT06394674
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Changhai Hospital
NSCLC
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
EGFR mutation-positive NSCLC patients have a higher risk of developing brain metastases. The prognosis is poor for patients presenting with brain or leptomeningeal metastases at any stage, particularly those with such metastases…
- Trial name
- NCT06945705
- Testing
- furmonertinib combined with anlotinib
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer (NSCLC), Brain Metastases
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
- Trial name
- NCT07365410
- Testing
- Furmonertinib, carboplatin, pemetrexed
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs.
- Trial name
- NCT06339242
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Non-Small Cell Lung Cancer
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated NSCLC.
- Trial name
- NCT05379803
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
The goal of this Single-arm, Phase II clinical trial is to learn whether ablation or stereotactic radiotherapy combined with furmonertinib can treat early-stage non-small cell lung cancer in patients who are inoperable or refuse…
- Trial name
- NCT07517640
- Testing
- furmonertinib, ablation, stereotactic body radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Adenocarcinoma of Lung
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
The purpose of this study is to determine the feasibility and effectiveness of ctDNA-MRD based adjuvant furmonertinib therapy in EGFR mutation-positive stage I lung adenocarcinoma patients after complete surgical resection.
- Trial name
- NCT05079022
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Non-small Cell Lung Cancer, EGFR G719X
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Furmonertinib, a newly-designed pan-EGFR-TKI with a trifluoroethoxypyridine-based molecule structure, has shown promising clinical efficacy in EGFR Ex19del/L858R/T790M/Ex20ins mutant advanced NSCLC with an acceptable safety…
- Conditions
- Non-small Cell Lung Cancer, EGFR G719X, EGFR L861Q, EGFR S768I
- Trial name
- NCT05548348
- Testing
- Furmonertinib 160 mg, Q.D.
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
- Conditions
- Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
- Trial name
- NCT05503667
- Testing
- Furmonertinib, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Alflutinib Mesylate Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model.
- Trial name
- NCT02973763
- Testing
- Alflutinib
- Volunteers
- 14 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Lung Cancer (NSCLC)
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Evaluate the efficacy and safety of neoadjuvant furmonertinib combined with anlotinib and chemotherapy in patients with resectable stage II-III EGFR mutation-positive non-small cell lung cancer.
- Trial name
- NCT06585644
- Testing
- Furmonertinib in combination with Anrotinib and chemotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer, Leptomeningeal Metastasis
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
The primary objective of this clinical study is to evaluate the efficacy of high-dose furmonertinib combined with bevacizumab and pemetrexed (triple therapy) in the treatment of non-small cell lung cancer (NSCLC) with…
- Conditions
- Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
- Trial name
- NCT06643000
- Testing
- furmonertinib
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Healthy Male Volunteers
Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers
To assess the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers in Fasting State or Following a High Fat Meal
- Trial name
- NCT03926182
- Testing
- AST2818 Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Allist Pharmaceuticals, Inc.
Advanced or Metastatic Non-small Cell Lung Cancer
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
To evaluate the efficacy, safety, recurrence site, recurrence pattern and resistance mechanism of 160mg furmonertinib as first-line therapy in advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR classical…
- Trial name
- NCT06674343
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Peking Union Medical College Hospital
Advanced NSCLC Patients With T790M
Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M
This study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring T790M mutation
- Trial name
- NCT03452592
- Testing
- Alflutinib
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
This study is designed as a prospective, multi-center investigation to explore the efficacy and safety of furmonertinib combined with upfront thoracic radiotherapy with or without metastatic lesion radiotherapy in subjects with…
- Trial name
- NCT07482605
- Testing
- Furmonertinib, Thoracic Radiotherapy (TRT)
- Volunteers
- 63 people
- Sponsor
- Jiangmen Central Hospital